CNO Financial at KBW Insurance Conference 2026: execution drives growth

CNO Financial said return on equity has already exceeded its prior 2027 target of 12%, versus an approximately 10% 2024 run rate, and it plans to issue higher targets in 2027 with an ambition to reach mid-teens, top-quartile ROE. Consumer agent count has increased for 14 consecutive quarters, broker-dealer assets reached $19 billion and rose 24% in Q2, and 70% of direct-to-consumer sales now originate outside television advertising. Management expects demographic demand and improved productivity to support growth, though its $170 million, three-year technology modernization program—targeted for completion by end-2028—will have limited near-term earnings benefit.

Analysis

CNO’s equity upside now depends less on another incremental sales beat and more on whether investors underwrite a durable mid-teens ROE trajectory despite the modernization spend. The key earnings-quality question is whether agent productivity and cross-sell persist as the mix shifts toward digitally sourced leads; digital lowers upfront acquisition expense volatility only if conversion and persistency remain intact. A credible 2027 target reset would support multiple expansion, but the stock is vulnerable if management frames the technology program primarily as risk remediation rather than a source of expense leverage.

The most underappreciated competitive effect is that CNO has limited direct exposure to Medicare Advantage underwriting stress that remains an overhang for HUM and, to a lesser extent, UNH. However, reduced MA benefits can redirect consumers toward Medigap, raising CNO’s lead flow while also inviting more carrier capacity and price competition; annual repricing mitigates medical-cost risk, but not distribution-cost inflation. Higher rates are mixed: they improve new-money annuity economics and investment income, yet make CDs and money-market funds a more formidable substitute, making retention of annuity spreads—not gross sales—the critical KPI.

Near term, this is a watch-for-guidance story rather than a conference-driven catalyst. Over 6-18 months, the $170m systems program creates execution asymmetry: a smooth rollout can reduce service friction and support agent retention, while delays or cost overruns would consume capital and expose legacy-platform operational risk. Consensus may be over-crediting demographic demand while underweighting the discretionary nature of the middle-income customer base if labor-market weakness, inflation, or credit stress intensifies.

Key Decisions for Investors

• Maintain or initiate a modest long CNO into 2027 target-setting; add only after quarterly disclosure confirms stable agent productivity, policy persistency, and advertising yield. Base case is multiple expansion on a credible mid-teens ROE path; thesis is falsified by sustained ROE below the current run-rate or a material increase in modernization budget/timeline.
• Use CNO as a relative-value long versus HUM over the next 3-6 months if Medicare Advantage benefit pressure persists: CNO captures potential Medigap substitution without MA medical-cost and Star-rating exposure. Exit if Medigap growth fails to translate into cross-sell/persistency or if HUM’s MA margin outlook stabilizes materially.
• Do not chase annuity-sales headlines while short rates remain elevated. Set an alert for declining money-market/CD yields or evidence of expanding credited-rate spreads; either would improve conversion economics and justify increasing CNO exposure. Conversely, rising competitive crediting rates without spread protection is a margin-risk signal.
• Monitor the 2027 capital framework for buyback capacity versus technology funding. A higher ROE target accompanied by unchanged capital return would be the cleaner rerating catalyst; reduced repurchases or new implementation charges would argue for trimming before the end-2028 conversion window.